| Literature DB >> 29629273 |
Hayne Cho Park1, Young-Ki Lee2, Kyung Don Yoo3, Hee Jung Jeon2, Seung Jun Kim4, Ajin Cho2, Jacob Lee5, Yang-Gyun Kim6, Sang-Ho Lee6, Sang-Oh Lee7.
Abstract
Patients receiving hemodialysis are vulnerable to infectious diseases due to their impaired immunity and high risk of exposure to pathogens. To protect patients, staff, and visitors from potential infections, each hemodialysis unit should establish and follow standard infection control and prevention measures. Therefore, clinical practice guidelines were developed by a working group of nephrologists and infection control specialists to provide evidence-based guidance for dialysis physicians and nurses, with the aim of preventing infection transmission and controlling infection sources in hemodialysis facilities. The areas of infection control covered by these guidelines include standard precautions, isolation strategies, vascular access, water treatment, cleaning/disinfecting/sterilizing, and vaccination. This special report summarizes the key recommendations from the Korean clinical practice guidelines for preventing the transmission of infections in hemodialysis facilities.Entities:
Keywords: Hemodialysis units; Hospitals; Infection control; Practice guideline
Year: 2018 PMID: 29629273 PMCID: PMC5875572 DOI: 10.23876/j.krcp.2018.37.1.8
Source DB: PubMed Journal: Kidney Res Clin Pract ISSN: 2211-9132
The system for categorizing recommendations
| Code | Level of evidence | Definition |
| A | High | Further research is very unlikely to change our confidence in the estimate of effect. |
| B | Moderate | Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. |
| C | Low | Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. |
| D | Very low | Any estimate of effect is very uncertain. |
| Category | Definition | |
| IA | Strongly recommended for implementation and strongly supported by well-designed experimental, clinical, or epidemiologic studies | |
| IB | Strongly recommended for implementation and supported by some experimental, clinical, or epidemiologic studies and a strong theoretical rationale; or an accepted practice supported by limited evidence | |
| IC | Required by national regulations, rules, or standards | |
| II | Suggested for implementation and supported by suggestive clinical or epidemiologic studies or a theoretical rationale (Level of evidence: Very low–High) | |
| Unresolved issues | Represents an unresolved issue for which evidence is insufficient or no consensus regarding efficacy exists (Level of evidence: Very low–High) | |
Isolation method and items according to the mode of transmission
| Component | Standard precaution should be followed in all cases | |||
|---|---|---|---|---|
|
| ||||
| Contact precaution | Contact precaution + | Droplet precaution | Airborne precaution | |
| Patient placement | Dialysis therapy in a single-patient room or cohort isolation or at the last sequence | Dialysis therapy in a negative pressure room or a single-patient room | ||
| Isolation sign | ○ | ○ | ○ | ○ |
| Hand hygiene | Hand asepsis with an alcohol-based hand rub or hand washing with antimicrobial soap and water | Hand washing with anti-microbial or nonantimicrobial soap and water | Hand asepsis with an alcohol-based hand rub or hand washing with antimicrobial soap and water | Hand asepsis with an alcohol-based hand rub or hand washing with antimicrobial soap and water |
| Separate medical equipment (blood pressure cuff or stethoscope, etc.) | ○ | ○ | × | × |
| PPE for staffs | ||||
| Gloves | ○ | ○ | × | × |
| Gown | ○ | ○ | × | × |
| Surgical masks | × | × | ○ | × |
| N95 mask | × | × | × | ○ |
| PPE for patient | Hand hygiene | Hand hygiene | Hand hygiene | Hand hygiene |
| Special container for biomedical wastes | ○ | ○ | ○ | ○ |
PPE, personal protective equipment.
Schedule for routine testing for HBV and HCV infections
| Patient status | On admission | Semiannual | Annual |
|---|---|---|---|
| All patients | HBsAg | ||
| Anti-HBc | |||
| Anti-HBs | |||
| Anti-HCV | |||
| Anti-HBs negative (< 10 mIU/mL) | HBsAg | ||
| Anti-HBs positive (≥10 mIU/mL) | Anti-HBs | ||
| Anti-HBs & anti-HBc positive | No additional HBV testing needed | ||
| Anti-HCV negative | Anti-HCV | ||
Figure 1Algorithm for HCV infection in hemodialysis patients
Ab, antibody; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CKD, chronic kidney disease; HCV, hepatitis C virus.
Adopted from the KDIGO guidelines (Kidney Int Suppl 2008;(109):S1–S99) [14].